ANDA 85632, held by Cycle. Quinidine Sulfate.
As of Nov 21, 2026, ANDA 85632 (Quinidine Sulfate), held by Cycle, was first approved by FDA on Aug 2, 1977, with 9 approved supplements and 0 published complete response letters.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Aug 2, 1977 | Original application | Approved | None posted |
| Product | Active ingredient | Marketing |
|---|---|---|
| Quinidine Sulfate300MG · tablet;oral | Quinidine Sulfate | Discontinued |
| Aug 28, 1996 | Supplement 15Manufacturing | Approved | None posted |
| Jul 15, 1996 | Supplement 16Labeling | Approved | None posted |
| May 9, 1991 | Supplement 14Labeling | Approved | None posted |
| May 9, 1991 | Supplement 13Labeling | Approved | None posted |
| Jun 6, 1990 | Supplement 11Labeling | Approved | None posted |
| Sep 12, 1989 | Supplement 10Labeling | Approved | None posted |
| Jan 24, 1989 | Supplement 8Manufacturing | Approved | None posted |
| Jan 24, 1989 | Supplement 7Manufacturing | Approved | None posted |
| Dec 30, 1988 | Supplement 1Bioequivalence | Approved | None posted |
| Aug 2, 1977 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. “What FDA's review says” is read by a model (Claude Haiku) from FDA's summary review PDF; a field is shown only if its numbers appear in the review, and each section links the review. Drugs@FDA and FDA complete response letters